3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

A compound of the formula:

• and the pharmaceutically acceptable salts and solvates thereof, wherein:
• A is selected from the group consisting of:
• wherein said A group is substituted with 1 to 6 substituents each independently selected from the group consisting of:
• unsubstituted alkyl;
• wherein said A group is substituted with 1 to 6 substituents each independently selected from the group consisting of:
• unsubstituted alkyl;
• wherein one or both rings of said A group is substituted with 1 to 6 substituents each independently selected from the group consisting of:
• unsubstituted alkyl;
• wherein one or both rings of said A group is substituted with 1 to 6 substituents each independently selected from the group consisting of:
• unsubstituted alkyl;
• B is:
• wherein R3 is selected from the group consisting of:
• —C(O)NR13R14,
• n is 0;
• R2 is selected from the group consisting of:
• hydrogen, OH, —C(O)OH, —SH, —SO2NR13R14, —NHC(O)R13, —NHSO2NR13R14, —NHSO2R13, —NR13R14, —C(O)NR13R14, —C(O)NHOR13, —C(O)NR13OH, —S(O2)OH, —OC(O)R13;
• R4 is independently selected from the group consisting of:
• hydrogen, cyano, halogen, alkyl, alkoxy, —OH, —CF3, —OCF3, —NO2, —C(O)R13, —C(O)OR13, —C(O)NHR17, —C(O)NR13R14, —SO(t)NR13R14, —SO(t)R13, —C(O)NR13OR14, and unsubstituted or substituted aryl,
• wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of:
• R9 groups;
• each R5 and R6 are the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, —CF3, —OCF3, —NO2, —C(O)R13, —C(O)OR13, —C(O)NR13R14, —SO(t)NR13R14, —C(O)NR13OR14, cyano, and unsubstituted aryl;
• each R7 and R8 is independently selected from the group consisting of:
• H, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, alkynyl and alkenyl;
• and wherein there are one or more substituents on said substituted R7 and R8 groups, wherein each substituent is independently selected from the group consisting of:
• a) halogen,
• b) —CF3,
• c) —COR13,
• d) —OR13,
• e) —NR13R14,
• f) —NO2,
• g) —CN,
• h) —SO2OR13,
• i) —CO2R13,
• j) —C(O)NR13R14,
• k) —NR13C(O)R14, and
• l) —NR13CO2R14;
• each R9 is independently selected from the group consisting of:
• —R13;
• each R13 and R14 is independently selected from the group consisting of:
• H and unsubstituted alkyl;
• each R15 is independently selected from the group consisting of:
• H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl;
• R17 is selected from the group consisting of:
• —SO2alkyl, —SO2aryl, —SO2cycloalkyl, and —SO2heteroaryl;
• R30 is selected from the group consisting of:
• alkyl, cycloalkyl, —CN, —NO2, or —SO2R15 provided that R15 is not H;
• and
• t is 0, 1 or 2.